Jasper Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Jasper Therapeutics

08/05/2023 12:24

* Jasper Therapeutics Inc  JSPR.OQ   JSPR.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Jasper Therapeutics
Inc
is for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $6.43​, above​ its last closing price
of $1.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.35       -0.36      -0.36     Met     0
 Sep. 30 2022  -0.34       -0.34      -0.32     Beat    6.6
 Jun. 30 2022  -0.32       -0.31      -0.29     Beat    7.4​
 Mar. 31 2022  -0.35       -0.35      -0.06     Beat    82.9
 ​​Dec.        -0.25       -0.34      -0.79     Missed  -130
 31 2021                                                
 Sep. 30 2021  -0.24       -0.28      -2.03     Missed  -634.8
                                                        ​
 This summary was machine generated May 8 at 11:24 GMT.  All
figures in US dollars  unless otherwise stated